p.79 抽出テキスト

321. Ezekowitz MD, Pollack CV, Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J 2018;39:2959–71. https:// doi.org/10.1093/eurheartj/ehy148 322. Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail 2016;4:870–80. https://doi.org/10.1016/ j.jchf.2016.07.012 323. von Lueder TG, Atar D, Agewall S, Jensen JK, Hopper I, Kotecha D, et al. All-cause mortality and cardiovascular outcomes with non-vitamin K oral anticoagulants versus warfarin in patients with heart failure in the food and drug administration adverse event reporting system. Am J Ther 2019;26:e671–8. https://doi.org/10.1097/MJT. 0000000000000883 324. Harrison SL, Buckley BJR, Ritchie LA, Proietti R, Underhill P, Lane DA, et al. Oral anticoagulants and outcomes in adults >/=80 years with atrial fibrillation: a global federated health network analysis. J Am Geriatr Soc 2022;70:2386–92. https://doi.org/10.1111/jgs. 17884 325. Malhotra K, Ishfaq MF, Goyal N, Katsanos AH, Parissis J, Alexandrov AW, et al. Oral anticoagulation in patients with chronic kidney disease: a systematic review and meta-analysis. Neurology 2019;92:e2421–31. https://doi.org/10.1212/WNL.00000000 00007534 326. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39: 1330–93. https://doi.org/10.1093/eurheartj/ehy136 327. Rhee TM, Lee SR, Choi EK, Oh S, Lip GYH. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:885548. https://doi.org/10.3389/fcvm. 2022.885548 328. Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH, Gerß J, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 2023;147:296–309. https://doi.org/10.1161/CIRCULATIONAHA.122. 062779 329. Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 2022;146:1735–45. https://doi.org/10.1161/ CIRCULATIONAHA.121.054990 330. De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 2021;32: 1474–83. https://doi.org/10.1681/ASN.2020111566 331. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369:1206–14. https://doi.org/10.1056/NEJMoa1300615 332. Wang TY, Svensson LG, Wen J, Vekstein A, Gerdisch M, Rao VU, et al. Apixaban or warfarin in patients with an on-X mechanical aortic valve. NEJM Evid 2023;2: EVIDoa2300067. https://doi.org/10.1056/EVIDoa2300067 333. Guimarães HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117–26. https://doi.org/10.1056/NEJMoa2029603 334. Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 2022;43:2783–97. https://doi.org/10.1093/eurheartj/ehac242 335. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612–76. https:// doi.org/10.1093/europace/euab065 336. Grymonprez M, Carnoy L, Capiau A, Boussery K, Mehuys E, De Backer TL, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2023;9:722–30. https:// doi.org/10.1093/ehjcvp/pvad070 337. Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2019;17:1064–72. https://doi.org/10.1111/jth.14457 338. Suwa M, Nohara Y, Morii I, Kino M. Safety and efficacy re-evaluation of edoxaban and rivaroxaban dosing with plasma concentration monitoring in non-valvular atrial fibrillation: with observations of on-label and off-label dosing. Circ Rep 2023;5:80–9. https:// doi.org/10.1253/circrep.CR-22-0076 339. Song D, Zhou J, Fan T, Chang J, Qiu Y, Zhuang Z, et al. Decision aids for shared decision-making and appropriate anticoagulation therapy in patients with atrial fibrillation: a systematic review and meta-analysis. Eur J Cardiovasc Nurs 2022;21:97–106. https://doi.org/10.1093/eurjcn/zvab085 340. Vora P, Morgan Stewart H, Russell B, Asiimwe A, Brobert G. Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States. Int J Clin Pract 2022;2022:6707985. https://doi.org/10. 1155/2022/6707985 341. Grymonprez M, Simoens C, Steurbaut S, De Backer TL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace 2022;24:887–98. https://doi.org/10. 1093/europace/euab303 342. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC working group on thrombosis—task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087–107. https://doi.org/10.1160/ TH13-06-0443 343. Pandey AK, Xu K, Zhang L, Gupta S, Eikelboom J, Cook O, et al. Lower versus standard INR targets in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Thromb Haemost 2020;120:484–94. https://doi.org/10.1055/s-0039- 3401823 344. Sanders P, Svennberg E, Diederichsen SZ, Crijns HJGM, Lambiase PD, Boriani G, et al. Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation. Eur Heart J 2024;45:2594–603. https://doi.org/10.1093/eurheartj/ehae365 345. ACTIVE Investigators; Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066–78. https://doi.org/10.1056/NEJMoa0901301 346. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503. https://doi.org/10.1016/S0140- 6736(07)61233-1 347. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol 2011;8:602–6. https://doi.org/10.1038/nrcardio.2011.112 348. ACTIVE Writing Group of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903–12. https://doi.org/10.1016/S0140-6736(06)68845-4 349. Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, et al. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open 2020;3:e200107. https://doi.org/10.1001/ jamanetworkopen.2020.0107 350. Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, et al. Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. Eur Heart J 2018;39:464–73. https://doi.org/10.1093/eurheartj/ehx730 351. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. Circulation 2020;142:40–8. https://doi.org/10. 1161/CIRCULATIONAHA.120.046048 352. Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, et al. Stroke outcomes in the COMPASS trial. Circulation 2019;139:1134–45. https://doi.org/10.1161/ CIRCULATIONAHA.118.035864 353. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 2019;381:1103–13. https://doi.org/10.1056/NEJMoa1904143 354. Senoo K, Lip GY, Lane DA, Büller HR, Kotecha D. Residual risk of stroke and death in anticoagulated patients according to the type of atrial fibrillation: AMADEUS trial. Stroke 2015;46:2523–8. https://doi.org/10.1161/STROKEAHA.115.009487 355. Meinel TR, Branca M, De Marchis GM, Nedeltchev K, Kahles T, Bonati L, et al. Prior anticoagulation in patients with ischemic stroke and atrial fibrillation. Ann Neurol 2021;89:42–53. https://doi.org/10.1002/ana.25917 356. Polymeris AA, Meinel TR, Oehler H, Hölscher K, Zietz A, Scheitz JF, et al. Aetiology, secondary prevention strategies and outcomes of ischaemic stroke despite oral anticoagulant therapy in patients with atrial fibrillation. J Neurol Neurosurg Psychiatry 2022;93:588–98. https://doi.org/10.1136/jnnp-2021-328391 357. Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S, et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with nonvitamin K antagonist oral anticoagulants for stroke prevention. Stroke 2019;50: 2168–74. https://doi.org/10.1161/STROKEAHA.119.025350 358. Purrucker JC, Hölscher K, Kollmer J, Ringleb PA. Etiology of ischemic strokes of patients with atrial fibrillation and therapy with anticoagulants. J Clin Med 2020;9:2938. https://doi.org/10.3390/jcm9092938 359. Paciaroni M, Caso V, Agnelli G, Mosconi MG, Giustozzi M, Seiffge DJ, et al. Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: the RENO-EXTEND study. Stroke 2022;53:2620–7. https://doi.org/10.1161/ STROKEAHA.121.038239 360. Smits E, Andreotti F, Houben E, Crijns H, Haas S, Spentzouris G, et al. Adherence and persistence with once-daily vs twice-daily direct oral anticoagulants among patients Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026